Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,444.41
(
-0.76%
)
US TECH 100
28,544.80
(
-0.86%
)
Dow Jones
49,638.80
(
-0.85%
)
Brent Oil
106.53
(
2.25%
)
Bitcoin
79,437.06
(
-2.00%
)
News Focus
News Focus
Post# of 447944
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

SovereignNinja5

Send PM Follow Ignore
Followers 5
Posts 262
Boards Moderated 0
Alias Born 07/03/2025

SovereignNinja5

Re: SovereignNinja5 post# 444320

Friday, 01/09/2026 10:26:06 AM

Friday, January 09, 2026 10:26:06 AM

Post# of 447944
Sarissa knew this drug was coming out and knew it would be high cost and positioned Vascepa to get used. The Fibrate market label change was part of it. Vascepa is a cheaper drug that works and this new drug has no reimbursement models. The PBM will shunt to Vascepa, not Fibrates or this new costly drug. Tier placement matters. Now factor in an authorized generic and a new patent.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News